Live tape
Top 8, mentions 7d9,221MRNA1,836 mentions▲ +0.09GOOGL1,655 mentions▲ +0.04META1,257 mentions▲ +0.04SNDK1,105 mentions▲ +0.10NVDA1,091 mentions▲ +0.08SPCX862 mentions▲ +0.08NKE733 mentions▲ +0.03MSFT682 mentions▲ +0.05

Equity · Healthcare

ICUI

ICU Medical, Inc. · NasdaqGS

$157.56 −2.74% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 37 sessions
$180 $120 26 May 17 Jul

The line runs $135 on 26 May through $157.56 on 17 July, on a scale from $120 to $180. Days the market did not trade hold the previous close, flat.

The chart above plots the price of ICUI over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 37 sessions over that window: $135 on 26 May 2026 through $157.56 on 17 July 2026.

Market cap $3.9B
P/E (TTM) 48.5
52-week range $108 – $162
Avg volume 71.8K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 20, 2026

ICUI insider trades

SEC Form 4

ICUI has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 25 November 2025.

Date Insider Type Shares Value
25 Nov 2025 Woolson Daniel VP, GM-Infusion Capital Sell 2,897 $441K
11 Nov 2025 FINNEY ELISHA W Sell 1,285 $180K
11 Nov 2025 Sanzone Virginia Ruth VP, General Counsel Sell 930 $132K
27 Aug 2025 Greenberg David C. Buy 1,200 $152K
14 Aug 2025 Jain Vivek Chairman and CEO Buy 21,929 $2.47M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
11 Nov 2025 FINNEY ELISHA W Option exercise 1,285 $133K
12 Sep 2025 Jain Vivek Chairman and CEO Gift 63,641

ICUI reported financials

SEC EDGAR XBRL

ICUI reported revenue of $2.2B for the fiscal year ended 31 Dec 2025. Net income over the same period was $732K.

Figure Reported Period
Revenue $2.2B 31 Dec 2025 fiscal year
Net income $732K 31 Dec 2025 fiscal year
Diluted EPS $0.03 31 Dec 2025 fiscal year
Total assets $4.0B 30 Jun 2026 at period end
Total equity $2.2B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ICUI earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.76 $552M
31 Mar 2026 Q1 2026 $1.20 $530M
31 Dec 2025 FY 2025 $0.03 $2.23B
30 Sep 2025 Q3 2025 $-0.14 $537M
30 Jun 2025 Q2 2025 $1.43 $549M
31 Mar 2025 Q1 2025 $-0.63 $605M
31 Dec 2024 FY 2024 $-4.83 $2.38B
30 Sep 2024 Q3 2024 $-1.35 $589M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ICUI institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a ICUI position for the quarter ended 30 Jun 2026 — a combined $123.6M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Citadel Advisors Added +60.9% shares 536,225 $78.6M
Point72 Asset Management Added +99.0% shares 165,469 $24.3M
AQR Capital Management Added +189.5% shares 44,188 $6.5M
Marshall Wace Added +60.4% shares 42,797 $6.3M
GAMCO Investors Held (±25%) −0.0% shares 23,912 $3.5M
D. E. Shaw & Co. New position 20,076 $2.9M
Millennium Management Trimmed −90.2% shares 6,620 $970K
Man Group Held (±25%) −22.1% shares 4,057 $595K

Source: SEC EDGAR 13F filings

ICUI fails-to-deliver

SEC CNS data

On 27 Jul 2026, 719 shares of ICUI failed to deliver (about $113K).

Settlement date Shares failed Notional % of shares out
27 Jul 2026 719 $113K 0.003%
16 Jul 2026 792 $125K 0.003%
09 Jul 2026 267 $41K 0.001%
08 Jul 2026 40 $6K <0.001%

Source: SEC fails-to-deliver (CNS) data